Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells

Hernigou, Philippe; Homma, Yasuhiro; Flouzat-Lachaniette, Charles-Henri; Poignard, Alexandre; Allain, J.; Chevallier, Nathalie; Rouard, Hélène

doi:10.1007/s00264-013-2017-z

Cited by 204 publications

(132 citation statements)

References 18 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…Positioning of the Jamshidi needle in the iliac wing was confirmed by fluoroscopy. BMA was collected in a 60-ml syringe in a series of discrete pulls on the plunger (targeting a collection of 5-10 ml per pull), with repositioning of the needle tip between pulls based on the reported enrichment of progenitor cells by Hernigou et al [13]. The BMA was processed using the ART bone marrow concentration system (Celling Biosciences, Austin, TX, USA) to produce a bone marrow concentrated cell preparation.…”

Section: Bone Marrow Collection and Processingmentioning

confidence: 99%

Treatment of discogenic back pain with autologous bone marrow concentrate injection with minimum two year follow-up

Pettine¹,

Suzuki

Sand

et al. 2015

International Orthopaedics (SICOT)

107

View full text Add to dashboard Cite

show abstract

Section: Bone Marrow Collection and Processingmentioning

confidence: 99%

Treatment of discogenic back pain with autologous bone marrow concentrate injection with minimum two year follow-up

Pettine¹,

Suzuki

Sand

et al. 2015

International Orthopaedics (SICOT)

107

View full text Add to dashboard Cite

show abstract

“…The number of colony-forming unit fibroblasts was determined as an indication of the number of MSCs present in the bone marrow aspirate before processing and in the bone marrowderived cell concentrate. The assay has been described previously [15,16]. For muscle, four biopsies were obtained from the gluteus medius and gluteus maximus at surgery; one muscle biopsy was for evaluation of fatty infiltration; and one biopsy muscle sample was examined by light microscopy after staining with hematoxylin-eosin, periodic acid Schiff, and Masson's trichrome to check fatty degeneration.…”

Section: Evaluation Of the Number Stem Cells In Bone And In Musclementioning

confidence: 99%

Ceramic-on-ceramic THA Associated With Fewer Dislocations and Less Muscle Degeneration by Preserving Muscle Progenitors

Hernigou

Roussignol

Delambre

et al. 2015

Clinical Orthopaedics &Amp; Related Research

Self Cite

View full text Add to dashboard Cite

Background Dislocation is a common complication after total hip arthroplasty (THA). Although the etiology of dislocation is multifactorial, longer-term changes in muscle such as atrophy may influence the risk of prosthetic dislocation. Biological differences in wear products generated by different bearing surfaces may influence differences in the appearance of periarticular muscle after THA; however, such bearing-associated differences to our knowledge have not been studied in vivo, and few studies have evaluated bearing-associated differences in dislocation risk. Questions/purposes (1) Is there a correlation between the postoperative risk of dislocation at revision and the bearing surfaces of the primary arthroplasty? (2) Is there a higher extent of fatty muscle atrophy on CT scan in hips with osteolysis (polyethylene hips) as compared with hips without osteolysis (ceramic-on-ceramic hips)? (3) Are these two abnormalities (bone osteolysis and fatty atrophy) associated with a decrease of mesenchymal stem cells (MSCs) in bone and in muscle? Methods We retrospectively evaluated 240 patients (240 hips) who had a THA revision (98% of which, 235 of the 240, were isolated acetabular revisions) and a normal contralateral hip. All patients had received the same implants for the primary arthroplasty (32-mm head) except for bearing surfaces (80 hips with ceramic-on-ceramic, 160 with polyethylene). No differences were noted between the groups in terms of age, sex, body mass index, proportion of patients who had a dislocation after the index arthroplasty but before the revision, and proportion of the patients with stem loosening in addition to acetabular loosening. Indications for revision generally were cup loosening. The revisions in the hips with polyethylene bearings generally had more acetabular bone loss, but the position of the center of the cup and the orientation of the cup were similar after reconstruction in the two groups. Before revision, osteolysis, muscle atrophy, and fatty degeneration were evaluated on CT scan and compared with the contralateral side. Bone muscle progenitors were evaluated by bone marrow MSCs and satellite cells for muscle. At revision, all the hips received the same implants with the same head diameter (32 mm) and a standard liner. Revisions were performed between 1995 and 2005. The followup after revision was at a mean of 14 years (range, 10-20 years) for Each author certifies that he or she, or a member of his or her immediate family, has no funding or commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article. (range, 10-20 years) for polyethylene hips, and there was no differential loss to followup between the groups. Results More hips with polyethylene liners at the time of index arthroplasty dislocated after revision than did hips with ceramic liners (18% [29 of 160] compared with 1% [one of 80]; odds ratio, 17.5; 95% confidence interval, 2....

show abstract

“…Previously reported clinically effective doses of MSC range from 1500 to 9000 CFU-F/mL depending on the diagnostic and the method of BMC delivery [5,11,20,10,8,21] . This wide range seems to be related to the huge interpersonal variability of MSC endowment [22] and the different protocols utilized for quantification, but it also might be associated to the different processed volumes of BM and BMC ( Table 2). Similarly, another parameter associated to BMC´s healing potential is the number of CFU-F per total nucleated cells which ranges from 25 to 39 CFU-F /106 TNC [10,5,11,21,23] .…”

Section: Discussionmentioning

confidence: 99%

Processing Volumes and Therapeutic Cellular Doses of Point of Care Bone Marrow Concentrates

Rodr韌uez

Seijas

Codinach

et al. 2016

International Journal of Orthopaedics

View full text Add to dashboard Cite

formulation of BMC make it difficult to circumscribe basic processing variables to generate them. We analyzed the influence of processing different Bone Marrow (BM) volumes over the formulation and deliverable cell dose of BMC METHODS: Main cellular populations were characterized in BMC manufactured and applied for autologous use during the same surgical procedure. To do this, Flow Cytometry and Fibroblastic Colony Forming Units (CFU-Fs) assays were used. RESULTS: Cell concentration of aspirates was not statistically influenced in the range of volumes analyzed. Consequently the quality of BM seems to be conserved in the range of volumes assayed. By using the protocol described, the quality of BMC traditionally defined as CFU-F per mL did not differ in the range of volumes assayed whereas total dose of CFU-F and other differentiated cells effectively changed. CONCLUSIONS:The volume of BM defines cellular doses arriving to the patient with statistically significant differences. Parameters currently used to describe the quality of BMC as CFU-F/mL appear to be directly influenced by working volumes and thus total cellular doses applied might better characterize these products. Finally, since it is uncertain what cells within BMC form part of its active substance, the quantification of main cell subsets could be helpful to better understand where, when and how these medicinal products work. ABSTRACT AIMS: Bone Marrow Concentrates (BMC) applied to treat several osteo-articular pathologies had reported positive clinical outcomes at short-to medium-term follow up. However, the diversity of indications reported and the lack of consensus describing the ORIGINAL ARTICLE Key words:

show abstract

Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells

Abstract: In normal human donors, bone marrow aspiration from 30 patients demonstrated a reduced mesenchymal stem cell number in aspirates obtained using a larger volume syringe (50 ml) as compared with a smaller volume syringe (10 ml).

Cited by 204 publications

References 18 publications

Treatment of discogenic back pain with autologous bone marrow concentrate injection with minimum two year follow-up

Treatment of discogenic back pain with autologous bone marrow concentrate injection with minimum two year follow-up

Ceramic-on-ceramic THA Associated With Fewer Dislocations and Less Muscle Degeneration by Preserving Muscle Progenitors

Processing Volumes and Therapeutic Cellular Doses of Point of Care Bone Marrow Concentrates

Contact Info

Product

Resources

About